Connect with us

Investment Advice

Forma Therapeutics IPO: Stock Goes Public on Nasdaq

Published

on

The Forma Therapeutics IPO launched on the Nasdaq market. It hit less than a month after the company filed with the SEC. As biotech companies successfully go public, Forma Therapeutics stock could be the next hit.

But is it a good investment opportunity? Here’s what we know…

Forma Therapeutics IPO: The Business

Forma Therapeutics is a biopharmaceutical company. It aims to develop and commercialize novel therapeutics to help patients with rare hematologic diseases and cancers. The company’s focus is sickle cell disease (SCD) and prostate cancer.

In 2019, Forma reorganized, filing from a limited liability company to a corporation. The company also named Frank Lee as CEO. He has experience running the global development and commercial strategy for Genentech’s immunology, ophthalmology and infectious diseases divisions. Forma’s chief medical officer is Patrick Kelly. He’s been with the company since 2016.

Now, the company wants to take its research to the next step. It hopes the money raised in the Forma Therapeutics IPO will help. Let’s look at what that’s going towards…

Forma Therapeutics Stock Funds Clinical Trials

Forma’s lead product is FT-4202. It’s an oral, once-daily therapy treatment for SCD. SCD is one of the most common single-gene disorders in the world. It can cause low hemoglobin levels (iron-containing protein in red blood cells), multi-organ damage and even early death.

In 2019, Forma completed the healthy volunteer portion. The company reported on the treatment’s impact on healthy volunteers. Currently, FT-4202 is in a placebo-controlled Phase I trial in SCD patients ages 12 and older. Forma aims to move into Phase II/III trial in the first half of 2021. Proceeds from the IPO will help complete Phase I.

The company’s other product is FT-7051. It’s in preclinical development for the treatment of prostate cancer, the second leading cause of death for men in the U.S. Prostate cancer cell growth is driven by androgen receptor activity, which Forma’s treatment aims to inhibit. Studies have shown almost all patients eventually develop resistance to treatment. This is a big obstacle for Forma.

In April 2020, Forma Therapeutics received approval from the FDA for its investigational new drug application. Forma plans to start a Phase I trial in the fourth quarter of 2020. Proceeds raised in the Forma Therapeutics IPO will help the process.

Other biotech companies are also working on clinical-stage drugs for these conditions. Some include Constellation Pharmaceuticals (Nasdaq: CNST), Imara (Nasdaq: IMRA) and Bluebird Bio (Nasdaq: BLUE).

And competition is only some of the risk involved in investing in Forma Therapeutics stock.

The Risks of Investing in Forma Therapeutics

In the company’s prospectus, there is a section called “Risks Associated with Our Business.” And the list isn’t short. Below is a summary of the risks Forma identified for investors:

  • Hasn’t generated revenue from drug sales to date and may never be profitable
  • Has significant operating losses and estimates losses will continue
  • Needs funding in addition to Forma Therapeutics IPO proceeds to prevent delays and discontinuation of product
  • Relies on top products, which may not get regulatory approval
  • If approval is granted, the company will be subjected to continuous regulatory review for an additional expense
  • Relies on third parties for clinical trials
  • Could experience manufacturing difficulties
  • Possible inability to obtain patent and other intellectual property

The company relies on producing approved treatments, which takes a lot of time and money. The good news is Forma’s operating expenses are lower. In 2018, the company had $154 million in operating expenses. That number went down to $141 million in 2019. And according the company’s financial data, it’s projected to go down to $129 million for 2020.

On the other hand, the company’s collaboration revenue is also decreasing. In 2018, revenue was $164 million. And in 2019, that number was $100.5 million. The company has no reported revenue for the three months ended March 31, 2020. But investors hope the trend doesn’t continue.

For more detailed financial data on Forma Therapeutics, you can go to the company’s prospectus here.

Forma Therapeutics stock hit the market. But when did it launch? And how did it perform?

Forma Therapeutics IPO: Stock Trades on Nasdaq

On June 18, 2020, Forma priced its IPO at $20 per share. This was above the original range of $16 to $18. Underwriters exercised their over-allotment option for a total offering of nearly 13.9 million shares. As a result, Forma Therapeutics raised almost $278 million.

The company started trading on Friday, June 19, 2020. Stock trades on the Nasdaq under the ticker symbol FMTX.

If you’re looking for the latest investment opportunities, Investment U is the place to be. Sign up for our free e-letter below! It’s full of useful tips and research from our experts. Whether you’re a beginner or an experienced investor, there’s something for everyone.

Forma Therapeutics stock closed at $39 a share on Friday. That’s a 95% return on its first day trading. And it means the Forma Therapeutics IPO was a success.

The post Forma Therapeutics IPO: Stock Goes Public on Nasdaq appeared first on Investment U.

—————-

By: Amber Deter
Title: Forma Therapeutics IPO: Stock Goes Public on Nasdaq
Sourced From: investmentu.com/forma-therapeutics-ipo-stock/
Published Date: Sat, 20 Jun 2020 13:00:33 +0000

Did you miss our previous article…
https://getinvestmentadvise.com/investment-advice/how-to-collect-safe-income/

Continue Reading

Investment Advice

Are These Marijuana Stocks Built For Long Or Short Term Success?

Published

on

Would You Invest In These Marijuana Stocks In 2021?

For the last several month’s investors have found a renewed interest in marijuana stocks. From mid-2020 to currently in 2021 cannabis stocks have been on the move. Many pot stocks from various niches have been rising in the market. Some marijuana stocks have not only reported record earnings but some have seen back-to-back all-time highs. With the amount of money being invested with the hopes of federal cannabis reform, people are trying to jump on board before the boat leaves the dock.

The cannabis sector as a whole has been on fire. Many companies in the cannabis industry have been preparing for what’s next to come. Meaning most cannabis companies are making operational adjustments to be able to adapt to the future of the cannabis industry. For example, 2 big-time cannabis companies both teamed up to make the biggest cannabis company on earth. Tilray Inc. and Aphria Inc. joined forces which have helped both companies market performance to a degree.

As well other companies have taken notice and may follow the same path. A lot is changing for the cannabis industry between legislation, more states going legal, and new regulations. All these variables play a factor in how this sentiment impacts the market. With more positive sentiment taking hold of the market is reflects in how well some marijuana stocks trade.

So far in 2021 cannabis stocks are moving up and seeing overall bigger gains. For this reason, many new and seasoned investors are looking to get involved and make some money. The cannabis industry is one of the fastest-growing markets in the world that is continuously expanding. The 2 cannabis stocks below are examples of when the sector is trending it resonates well with how marijuana stocks can or will trade.

Pot Stock Watch List This Month

  1. Green Lane Holdigns Inc. (NASDAQ:GNLN)
  2. Liberty Health Sciences Inc. (OTC:LHSIF)

Green Lane Holdigns Inc.

Green Lane Holdigns Inc. has been of the many marijuana stocks trying to climb higher in a volatile market. Back in 202 GNLN stock saw its price fluctuate quite often. This price fluctuation allowed for good entry points before GNLN stock had a spike in trading. Like many marijuana stocks, 2021 gave the cannabis market a nice push to start the new year. With Green Lane 2021 was no different.

In the first 2 weeks of the new year, GNLN stock shot up 25 percent in trading as it was starting to dip from this point. Even though Green Lane closed out the first month of the new year with a drop from previous highs in January the following month was a different story. Currently GNLN stock in February has been able to recover from January’s dip. 

The company has been able to even reach higher highs than last month. Within the first trading week of February, GNLN stock saw gains of 27 percent. This was a much-needed momentum booster to help the company recover from its trading at the close of January. So far for in February GNLN stock has had a nice upward push in the market showing over 60 percent gains in trading. This current momentum has signaled to investors that Green Lane may be a marijuana stock to watch in 2021.

[Read More]

Liberty Health Sciences Inc.

Liberty Health Sciences Inc. has been an interesting cannabis stock to watch. Like many other cannabis businesses, it’s going to take more than a pandemic to stop the company from expanding. Back in January, the company announced that it will be opening a new location adding to its current portfolio of dispensaries. The Company plans to open two more dispensaries by the end of February 2021 with much more in the works.

Although in 2020 LHSIF stock traded mostly sideways with subtle spikes in trading the new year has provided a strong push in trading. Starting from December 21st LHSIF stock started to bounce and began to climb in the market. From the 21st to the 31st of December LHSIF stock shot up 90 percent. For those who held their position until this point, they made a healthy return on their investment. Pushing into the new year the company was able to sustain its market momentum and keep pushing up in the market.

In the first 14 days of trading of the new year LHSIF stock has a 13 percent increase in trading. The remainder of January’s trading resulted in a small dip. Yet overall gains for the first month of 2021 for LHSIF stock was an increase of 8 percent. This was a subtle push that helped the company sustain its current market position. Now that we have entered February LHSIF has continued to trade up in the market. Currently for the month of February LHSIF stock is up over 25 percent. If the company can continue this momentum it would intrigue more people to keep an eye on this marijuana stock.

The post Are These Marijuana Stocks Built For Long Or Short Term Success? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

—————-

By: Daniel Chase
Title: Are These Marijuana Stocks Built For Long Or Short Term Success?
Sourced From: marijuanastocks.com/are-these-marijuana-stocks-built-for-long-or-short-term-success/
Published Date: Thu, 11 Feb 2021 13:30:07 +0000

Did you miss our previous article…
https://getinvestmentadvise.com/investment-advice/price-to-earnings-ratio-defined-p-e-ratio-formula/

Continue Reading

Investment Advice

Price to Earnings Ratio Defined (P/E Ratio Formula)

Published

on

Trying your hand at the stock market? Chances are, you’ve come across the term “P/E ratio”. If you’re like many who are new to the stock market, you’ve looked at this phrase and asked yourself, “What in the world is that?” 

P/E ratio, otherwise known as the price-to-earnings ratio, is a formula that investors use to determine the value of a company’s share. It is one of the most common formulas used to determine the value of a stock. The formula compares the price of a company’s share to the earnings per share (EPS) of the company in order to determine how much an investor is paying for $1 of the company’s earnings. Let’s take a deeper dive into the P/E formula. Use the links below to jump ahead to a section of your choosing. 

P/E Formula and Calculation 

First thing’s first: let’s learn the price to earnings ratio formula and how to calculate it. The price-to-earnings ratio formula is as follows: the price of a single share of a company’s stock (What is a stock?), divided by the company’s earnings per share (EPS). The ratio of these two variables will tell you exactly how much an investor is spending for a single dollar of the company’s earnings. 

Finding the cost of a company’s stock is extremely simple. In order to find the price of a single share of a company’s stock, all you need to do is enter the company’s stock ticker symbol (the series of characters that represents that company on the stock market) into a finance website, such as investor.gov. You’ll quickly find the current cost for a single share of that company’s stock. Google also keeps an up-to-date Market Summary for the prior day’s stock market, so a quick Google search will often bring exactly the answer you’re looking for. 

Determining a company’s earnings per share (EPS) can be a bit trickier. Earnings per share are broken down into 2 categories: trailing earnings and forward earnings. Trailing earnings, often shortened to TTM, are the company’s core earnings over the trailing, or prior, 12 months. This number is the profit that the company has generated over the past 12 months of business. Remember that we’re talking about the net income of a business, rather than the gross income (Need a refresher? Learn more about gross income vs net income.). P/E ratios calculated with trailing earnings are known as the trailing P/E (P/E TTM). Forward earnings, on the other hand, are the predicted earnings that the company will generate over the next 12 months. P/E ratios calculated using forward earnings are known as the forward P/E. Both types of earnings are divided by the total number of public shares on the market in order to generate their EPS. More on this later. 

Let’s try out an example. Say you’re looking to determine the trailing P/E of a fictional company AlphaBet Corporation, known on the stock market as ABC. Their share price is currently at $50 per share. Their trailing earnings per share is $5. Divide the $50 per share by the $5 EPS, and you’re left with a P/E of 10. This means that investors are paying $10 for every $1 in earnings per share. 

Understanding P/E Ratio 

So, ABC has a P/E of 10. What does that mean for you? 

In the most general sense, the lower a P/E ratio, the less an investor is paying for each dollar of a company’s earnings per share. A higher P/E ratio means that an investor is paying more per EPS. But, unfortunately, determining which stock to buy isn’t as simple as “look for the lowest P/E ratio”. 

It is imperative to remember that everything on the stock market is relative. “Good” and “bad” numbers are different for each and every industry. An electronics company and an automotive company are functioning in two vastly different landscapes. Therefore, in order to determine what is a good price to earnings ratio, you’ll need to understand the landscape of P/E ratios in the industry. Look at similar companies’ P/E ratios to better understand the relative value of your company’s P/E ratio. If ABC’s price-to-earnings ratio seems extremely high as compared to other companies in the industry, it may be an overvalued stock. On the other hand, if it seems extremely low as compared to other companies in the industry, it may be a very valuable stock. 

Let’s try another example. We’ve already determined that ABC’s price is $50 per share, earnings are $5 per share, and P/E is 10. A competitor, DOG, also has stock for $50 per share. Their earnings, on the other hand, are $2 per share, making their PE 25 (50/2=25). An investor would pay $10 for every $1 of ABC’s earnings per share, but they’d have to pay $25 for every $1 of DOG’s earnings per share. With a better understanding of the landscape, we can see how ABC sits relative to its competitors. 

A company’s price to earnings ratio may also be looked at relative to itself. Remember those two types of earnings we reviewed earlier? We can compare a company’s trailing P/E to their forward P/E to better understand the value of a stock. A company with a high trailing P/E ratio may have been rather unprofitable the prior 12 months because theywere preparing to ramp up business substantially, and took on a number of upfront costs. They may be expecting a boom of profits over the forward 12 months, leaving them with a substantially lower forward P/E. By reviewing these numbers in comparison to each other, we may see an opportunity for a long-term investment. 

Limitations of the P/E Ratio 

While the price to earnings ratio is certainly one of the most widely used calculations among stock market investors and analysts, it’s not a cut and dry way to determine a good or bad stock. It gives investors a good understanding of the value of stock in a particular moment, but it certainly has its short-comings. 

Just as the stock market is relative, it’s also in a constant state of fluctuation. It is re-evaluated and recalculated constantly. Why does this matter when it comes to the price to earnings ratio? Well, just look at the variables we use to determine the P/E ratio. 

First, we have the “price” of the price-to-earnings ratio: the cost of a single share of a company’s stock. Stock prices fluctuate every single day based on supply, demand, current events, and more. Typically, the cost of a company’s stock will be reported as the cost that it was when the stock market closed the prior day. Each time a company’s stock price changes, their P/E ratio will change. Certain companies may tend to have a greater fundamental volatility than others, leaving their stock price changing substantially each and every day. Even those with low fundamental volatility experience routine fluctuation. 

Next, we have the “earnings” in the price-to-earnings ratio. Both trailing and forward P/E ratios have their limitations. Trailing P/E can feel like the more reliable of the two numbers because it’s based on facts. We take their actual earnings over the prior 12 months into account. But, in many situations, a company’s prior 12 months may have little to do with their next 12 months. As mentioned earlier, a company may have spent heavy the prior 12 months in preparation to ramp up the next 12 months. The trailing P/E won’t show us any of that. The forward P/E, on the other hand, is based on predictions. And predictions are quite educated guesses, but at the end of the day predictions are still guesses. A company may fall short of their predicted earnings or blow completely past them. 

Looking to try your hand at the stock market? Don’t go at it alone. Consider opening an investment account with Mint. We believe that there’s no “one-size-fits-all” approach to investment. That’s why we offer a variety of investment partners, suited to each particular need. Let’s find the best to suit yours. 

The post Price to Earnings Ratio Defined (P/E Ratio Formula) appeared first on MintLife Blog.

—————-

By: Mint
Title: Price to Earnings Ratio Defined (P/E Ratio Formula)
Sourced From: mint.intuit.com/blog/investing/price-earnings-ratio/
Published Date: Tue, 25 Aug 2020 19:37:02 +0000

Did you miss our previous article…
https://getinvestmentadvise.com/investment-advice/will-marijuana-banking-be-apart-of-federal-cannabis-reform/

Continue Reading

Investment Advice

Will Marijuana Banking Be Apart Of Federal Cannabis Reform?

Published

on

The Cannabis Industry VS Financial Institutions

As marijuana stocks and the cannabis industry as a whole awaits federal cannabis reform the sector keeps trending. Now if the U.S. can federally decriminalize cannabis some analysts feel it may cause some cannabis stocks to rally. As well as many new doors will that can open. For one many new markets will look to join the U.S. cannabis industry. Furthermore, with federal cannabis reform, it could be the start of initiating a banking system for the industry.

Currently due to cannabis still being federally illegal banks can not take money from a cannabis-related business. From the time states started going legal, it has been an issue that has yet to be resolved. The cannabis industry is one of the fastest-growing industries in the world, especially in the United States. Politicians have been working to pass various pieces of cannabis legislation.

The one bill that would be beneficial to the industry is known as the SAFE Banking Act. This bill would allow banks to accept money from cannabis-related businesses. On March 7, 2019, the bill was introduced to the U.S. House of Representatives by Ed Perlmutter and was introduced to the Judiciary and Financial Services Committees. Back in 2019, the Financial Services Committee voted 45 to 15 to advance the bill to the full House.

The SAFE Banking Act provisions were included in the HEROES Act COVID-19 relief bill passed in the U.S. House in May 2020. They were again included in a bill approved by the house 214–207 in October. A push to include the SAFE Banking Act provisions in the end-of-year COVID-19 stimulus failed, though hope remained it could pass in 2021 if reintroduced.

How Will The Cannabis Industry Work With Banks

When it comes to any business you can think having startup capital is important. Now not every person with money is willing to invest in a new venture which makes finding that more of a task. Especially with cannabis-related business and right now banks are no help. For a business to acquire a line of credit or some type of lending your business must be able to have some type of financial record.

This usually tells banks and lenders how good you are at paying things back and how reliable you are to do so. The bigger obstacle for cannabis businesses is how do you show you are trustworthy with no credit history. Once again this due to financial institutions not working with cannabis businesses. Let’s look at a few steps to help jump over some red tape.

First, you should start a new business that is a separate company from your personal credit. This will help when it comes time to do your taxes. The second step to take is you need to register for your EIN number. Next thing to do is open a new bank account and make sure you can show that you have continuous income which shows financial stability. Again with banks not accepting cannabis money the last step may be next to impossible to do.

[Read More]

Will Cannabis Banking Actually Happen?

The way financial institutions offer other industries various banking options is not the same for the cannabis industry. Although there is some grey area with cannabis and banks yet most banks won’t offer services for how high risk the industry is. This leaves many cannabis businesses left out from what other traditional retail businesses would have. Look past the risk banks also look at taking cannabis money as to much work. This would result in following regulations and keeping data on all money. This process has been established by the Bank Secrecy Act of 1970. Also, working with the large amounts of cash cannabis businesses generate may affect how a bank can operate.

With this roadblock between banks and cannabis money, it shuns cannabis businesses from establishing a form of credit. This issue alone is why the industry operates only in cash with very few places to keep it. Also, this issue can do much harm to future relationships with other companies and businesses. If a cannabis business can not establish a credit history no lender or bank can help. That’s why it’s important to have an industry as big as cannabis have some form of credit being reported to credit companies. This will tell other lenders and banks that a particular business is profitable enough to pay back any loans.

What Will The Future Of Cannabis Banking Become

It’s wild to think that an industry that is generating a high volume of cash is being blocked from showing the reliability needed to secure lending. Some feel if the cannabis business can earn the trust of financial institutions by being transparent with its earnings. This may be a step to banks feeling more comfortable with working with a cash-intensive business. Hopefully, with federal cannabis reform, it will help push cannabis banking in the direction needed to help out the industry.

The post Will Marijuana Banking Be Apart Of Federal Cannabis Reform? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

—————-

By: J. Phillip
Title: Will Marijuana Banking Be Apart Of Federal Cannabis Reform?
Sourced From: marijuanastocks.com/will-marijuana-banking-be-apart-of-federal-cannabis-reform/
Published Date: Tue, 09 Feb 2021 18:34:56 +0000

Continue Reading

Trending